US Stocks Start Week On Lower Note, Dow Drops Over 100 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Monday.
UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help COVID-19 Patients
According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID.
The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival.
Blood Clot Drug Totally Ineffective as Post-covid Treatment, Research Finds
-FT
https://www.ft.com/content/db1e6c05-b8bb-429e-8cbd-8ea0dde58bf0
Bristol Myers Squibb Data At ASH 2022 Highlight Innovative Therapeutic Platforms Across A Range Of Blood Diseases
New data from our multiple myeloma portfolio across targets and molecular approaches show significant progress toward our goal of transforming the treatment paradigm and improving outcomes for patients
Multiple first
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
Credit Suisse has initiated coverage on Bristol-Myers Squibb Co (NYSE:BMY) with a Neutral rating and a price target of $78. The analysts…
Where Bristol-Myers Squibb Stands With Analysts
Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
8 Analysts Have This to Say About Bristol-Myers Squibb
Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY) within the last quarter: Bullish Somewhat Bullish Indifferent…
Credit Suisse Initiates Coverage On Bristol-Myers Squibb with Neutral Rating, Announces Price Target of $78
Credit Suisse analyst Trung Huynh initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Neutral rating and announces Price Target of $78.
OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer
OncoSec Medical Incorporated (NASDAQ:ONCS) announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb Co’s (NYSE:BMY) intravenous Opdivo…